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https://doi.org/10.1016/j.celrep.2020.107658SUMMARYNeonatally transplanted human glial progenitor cells (hGPCs) can myelinate the brains of myelin-deficient
shiverer mice, rescuing their phenotype and survival. Yet, it has been unclear whether implanted hGPCs
are similarly able to remyelinate the diffusely demyelinated adult CNS. We, therefore, ask if hGPCs could
remyelinate both congenitally hypomyelinated adult shiverers and normal adult mice after cuprizone demy-
elination. In adult shiverers, hGPCs broadly disperse and differentiate as myelinating oligodendrocytes after
subcortical injection, improving both host callosal conduction and ambulation. Implanted hGPCs similarly re-
myelinate denuded axons after cuprizone demyelination, whether delivered before or after demyelination.
RNA sequencing (RNA-seq) of hGPCs back from cuprizone-demyelinated brains reveals their transcriptional
activation of oligodendrocyte differentiation programs, while distinguishing them from hGPCs not previously
exposed to demyelination. These data indicate the ability of transplanted hGPCs to disperse throughout the
adult CNS, to broadly myelinate regions of dysmyelination, and also to be recruited as myelinogenic oligo-
dendrocytes later in life, upon demyelination-associated demand.INTRODUCTION
Oligodendrocytes are the sole source of myelin in the adult CNS,
and their loss or dysfunction is at the heart of a wide variety of
diseases of both children and adults. In children, the hereditary
leukodystrophies accompany cerebral palsy as major sources
of demyelination-associated neurological morbidity. In adults,
demyelination contributes not only to diseases as diverse as
multiple sclerosis and white matter stroke but also to a broad va-
riety of neurodegenerative and neuropsychiatric disorders (Lee
et al., 2012; Roy et al., 2004; Tkachev et al., 2003). As a result,
the demyelinating diseases have evolved as especially attractive
targets for cell-based therapeutic strategies (Archer et al., 1994,
1997; Br€ustle et al., 1999; Kondo and Duncan, 2016; Shihabud-
din et al., 2004; Tamaki et al., 2009; Windrem et al., 2002, 2004,
2008; Yandava et al., 1999; Zhang and Duncan, 2000), as re-
viewed in Franklin and Goldman (2015); Goldman et al., 2012,
and Goldman (2016). Prior studies have established the ability
of neonatally transplanted human glial progenitor cells
(hGPCs)—also referred to interchangeably as oligodendrocyte
progenitor cells (OPCs) or NG2 cells (Nishiyama et al., 2009)—
to myelinate the hypomyelinated shiverer brain and to rescue
both the neurological phenotype and lifespan of mice treated
as newborns (Wang et al., 2013; Windrem et al., 2004, 2008).
Furthermore, a variety of enriched preparations of hGPCs,This is an open access article undderived from both human brain and pluripotent stem cells,
have been shown capable of remyelinating focal lesions of the
adult brain and spinal cord (Buchet et al., 2011; Piao et al.,
2015; Windrem et al., 2002). Yet, these latter studies were
done in models of focal demyelination; it has remained unclear
whether hGPCs are able to migrate extensively in adult brain tis-
sue, as would be required for the repair of diffusely demyelinated
tissue. Indeed, to our knowledge, no previous study has system-
atically assessed the ability of hGPCs to either migrate within or
remyelinate brain tissue demyelinated in adulthood.
To that end, in this study, we asked if fetal-brain-derived
hGPCs might exhibit sufficient migration and expansion compe-
tence in the adult environment to serve as therapeutic vectors for
acquired, adult-onset demyelination. In this regard, recent
studies have supported the readiness with which axons can re-
myelinate after either congenital or focal adult demyelination if
provided myelinogenic cells (Buchet et al., 2011; Duncan et al.,
2009; Ehrlich et al., 2017; Piao et al., 2015; Windrem et al.,
2008). In parallel, other recent reports have highlighted the
cell-intrinsic loss of myelination competence by endogenous
glial progenitor cells as the basis for remyelination failure in dis-
orders as diverse as progressivemultiple sclerosis (Nicaise et al.,
2017, 2019) and Huntington disease (Ferrari Bardile et al., 2019;
Osipovitch et al., 2019), suggesting that the introduction of new,
myelination-competent glial progenitors might be sufficient toCell Reports 31, 107658, May 19, 2020 ª 2020 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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here if hGPCs delivered directly into the adult brain could remye-
linate axons in the setting of diffuse demyelination, as might be
encountered clinically in progressive multiple sclerosis and other
causes of multicentric adult demyelination.
To do so, we used three distinct experimental paradigms. We
first asked if hGPCs could effectively disperse within and myeli-
nate the brains of adultMBPshi/shi mice, which carry the shiverer
mutation in the gene encoding myelin basic protein (MBP); this
mutation precludes MBP expression and abrogates develop-
mental myelination in these mice. By these means, we assessed
the ability of hGPCs to restore myelin to the congenitally hypo-
myelinated adult brain, as might be encountered in the late post-
natal treatment of a hypomyelinating leukodystrophy. Second,
we next asked if neonatally engrafted hGPCs could respond to
cuprizone-induced adult demyelination by generating new oligo-
dendrocytes and myelinating demyelinated axons, so as to
assess the ability of already-resident hGPCs to remyelinate pre-
viously myelinated axons, as might be demanded of human
parenchymal progenitor cells after acquired demyelination.
Third, we then asked if hGPCs transplanted into the adult brain,
after cuprizone demyelination, could remyelinate denuded
axons, asmight be anticipated in the cell-based treatment of dis-
orders such as progressive multiple sclerosis.
We found that in each of these experimental paradigms, the
hGPCs, whether engrafted neonatally or transplanted into
adults, effectively dispersed throughout the forebrains, differen-
tiated as oligodendroglia and myelinated demyelinated axons.
These data suggested that transplanted hGPCs are competent
to disperse broadly and differentiate as myelinogenic cells in
the adult brain and, most critically, that they are able to remyeli-
nate previously myelinated axons that have experienced myelin
loss. On that basis, we also asked what the transcriptional con-
comitants of demyelination-associated mobilization might be in
resident hGPCs. We, therefore, isolated hGPCs from neonatally
chimerized brains after the cessation of cuprizone demyelin-
ation, and used RNA sequencing (RNA-seq) analysis to define
those genes and cognate pathways induced by antecedent cu-
prizone demyelination. Together, these studies establish the
ability of hGPCs to remyelinate demyelinated lesions of the adult
human brain and provide a promising set of molecular targets for
the modulation of this process in human cells.
RESULTS
Adult shiverer Mice Exhibit Myelination following hGPC
Delivery
To assess the ability of donor hGPCs to disperse and differen-
tiate as oligodendroglia in the adult brain, we introduced
CD140a-sorted fetal hGPCs into young adult shiverer3 rag2/
immune-deficient mice (Sim et al., 2011), as well as into two nor-
mally myelinated immunodeficient control lines, namely, rag1/
on a C57BL/6 background and rag2/ on C3H. All mice were in-
jected after weaning, over the range of 4–12 weeks of age; the
shiverers were all injected between 4–6 weeks. A total of 22
mice (8 shiverers and 14 normally myelinated rag null mice,
both rag1/ and rag2/) were injected bilaterally in the corpus
callosum (CC), with injections of 53 104 hGPCs per hemisphere.2 Cell Reports 31, 107658, May 19, 2020All 8 shiverers and 6 of the controls were sacrificed 12–15 weeks
later at 19–22 weeks of age, and the remaining 8 control mice
were sacrificed at approximately 1 year of age. The brains of
all mice were examined for donor cell dispersal and oligodendro-
cytic differentiation as well as for MBP immunoreactivity, which
was necessarily donor derived in the shiverer context.
The hGPCs were both highly migratory and robustly myelino-
genic in the adult brain. By 12–15 weeks after transplant, the in-
jected cells had dispersed broadly throughout the forebrain, as is
typically observed in similarly treated neonates (Windrem et al.,
2008), with a near-uniform distribution of donor cells noted
throughout the white matter in both congenitally dysmyelinated
shiverers (Figure 1A) and normally myelinated (Figure 1B) mice.
Myelinogenesis was robust in the shiverers, with dense myelina-
tion of the corpus callosum (Figures 1C–1F). Importantly, at the
19-week time-point assessed, the callosal densities of all human
cells, as well as hGPCs, oligodendrocytes, and astrocytes, were
all significantly and substantially higher in the recipient shiverer
brains than in their myelin wild-type (WT) controls (Figures 1G–
1M), indicating the overwhelmingly competitive advantage of
the human donor cells in the shiverer environment. In myelin
WT control brains, whether examined at either 5 or 12 months,
these cells also expanded and engrafted but largely remained
as progenitors (Figure 1H). These data indicated that CD140a-
sorted hGPCs are able to migrate broadly throughout the young
adult mouse brain, that the dispersal of these cells is not
impeded by adult brain parenchyma, and that robust myelination
of still-viable axons can begin even after a several months’
absence of mature myelin in the affected brain.
Resident hGPCs Can Remyelinate the Cuprizone-
Demyelinated Corpus Callosum
Cuprizone is a well-studied copper chelator, the chronic oral
administration of which causes mitochondrial dysfunction that
is both earliest and most prominent in myelinating oligodendro-
cytes (Morell et al., 1998). Its oral administration results in diffuse,
relatively synchronous demyelination, which has beenwell-char-
acterized in a variety of mouse strains and ages (Stidworthy
et al., 2003). Cuprizone-induced demyelination is more repro-
ducible than any other current model of demyelination, has little
systemic toxicity at demyelinating doses, is associated with little
acute axonal injury or neuronal loss, and is relatively non-inflam-
matory, except for local microglial activation (Matsushima and
Morell, 2001). To assess the ability of hGPCs to remyelinate
newly demyelinated adult axons, we used dietary cuprizone to
induce central demyelination and followed the responses of
both already-resident and later-introduced hGPCs to that myelin
loss.
We began by asking if hGPCs already resident within the
mouse white matter could differentiate as oligodendrocytes
and remyelinate denuded axons after cuprizone challenge. We
first assessed the effects of cuprizone on rag1/ 3 C57BL/6
mice and confirmed previous observations (Hibbits et al., 2009,
2012) that a 12-week course of cuprizone induced the wide-
spread loss of transferrin (TF)-defined oligodendrocytes in the
corpus callosum, with no detectable loss of resident mouse
GPCs. We then asked if neonatally implanted hGPCs could simi-
larly tolerate cuprizone exposure and, if so, whether they
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Figure 1. hGPCs Mediate Robust Myelination
after Transplantation into the Adult shiverer
Brain
hGPCs proved both highly migratory and robustly
myelinogenic, after delivery at 4–6 weeks of age to the
hypomyelinated adult shiverer (MBPshi/shi) 3 rag2/
brain.
(A) By 19–20 weeks of age—13–15 weeks after
transplant—the injected cells had dispersed as
broadly as is typically observed in similarly trans-
planted shiverer neonates (Windrem et al., 2008,
2014), with a near-uniform distribution of donor cells
noted throughout the forebrain white matter.
(B) hGPCs delivered to myelin wild-type (WT) rag2/
mice distributed throughout both gray and white
matter, although with less mitotic expansion than that
noted in hypomyelinated shiverer recipients.
(C) Oligodendrocyte differentiation and myelino-
genesis by donor hGPCs delivered to the shiverer 3
rag2/ brain at 6 weeks of age was robust, with
dense myelination of the corpus callosum and fimbria
by 19–20 weeks.
(D) A higher power image of (C) shows the high pro-
portion of donor cells in the now humanized host white
matter.
(E) Confocal imaging through the callosum of an adult
engrafted shiverer shows a dense array of myelinating
human oligodendrocytes. (E’) A higher-power field
with orthogonal views.
(F) A single, oligodendrocyte myelinating multiple local
axons in its vicinity. CNP, blue; MBP, green; hN, red.
(G and H) Both shiverer (shi) and myelin WT recipients
exhibited substantial donor hGPC colonization after
adult transplantation, whereas the callosal densities of
all human cells (G) and PDGFaR-defined hGPCs (H)
were significantly higher in shiverer rather than WT re-
cipients. In the latter, the densities of all donor cells and
identified hGPCs (G andH) did not differ between 5 and
12months of age, suggesting that donor cell expansion
in the adult WT brain occurred within the first several
months after transplant. *p < 0.05; ***p < 0.001.
(I) The density of transferrin (TF)-defined human oligodendroglia was 5- to 10-fold higher in adult-transplanted shiverers than in WT hosts, when both were
assessed 3 months after graft, at 5 months of age. *p < 0.05; ***p < 0.001.
(J) A smaller proportion of the donor cell populationmatured asGFAP-defined astrocytes; thesewere significantlymore abundant in the shiverer than inWT hosts.
*p < 0.05.
(K–M) Representative images of anti-human NG2-defined donor-derived hGPCs (K), anti-human GFAP-defined astrocytes (L), and TF/human nuclear antigen
(hNA) co-expressing donor-derived oligodendrocytes (M), in 19-week-old shiverer white matter, 13 weeks after transplant.
Scale bars: 100 mm (C and D) and 50 mm (I–K).
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nate adult-demyelinated axons. To that end, we transplanted
rag1/ 3 C57BL/6 mice on post-natal day 1 with human fetal
A2B5+/PSA-NCAM GPCs, delivered as 105 cells per hemi-
sphere into the corpus callosum bilaterally. For this study, we
used A2B5+/PSA-NCAM-sorted GPCs rather than CD140a-
defined GPCs, in light of the cell numbers needed for this exten-
sive experiment; the two antigenic phenotypes are lineally
related and behave analogously in vivo in terms of both their
migration and myelinogenic competence (Sim et al., 2011).
This protocol results in widespread colonization of the recipient
brains by hGPCs, which ultimately replace many—and typically
most—of the host murine GPCs (Windrem et al., 2014). The
resultant human glial chimeric mice were then given dietary cu-
prizone (0.2% w/w) as a food additive, beginning at 4 monthsof age; by this time, the NG2+ hGPCs have largely replaced
mouse callosal NG2+ cells (Windrem et al., 2014). The experi-
mental mice were left on the cuprizone diet for 12 weeks, and
littermate controls were maintained on a normal diet (Figure 2A).
The density of human cells in the host whitematter, as well as the
percentage of those cells that differentiated as oligodendro-
cytes, was calculated for both cuprizone-treated and control
mice at the start of the dietary manipulation, as well as at each
of 3 different time points thereafter: (1) immediately after cupri-
zone cessation, (2) after 8 weeks’ recovery, and (3) after
20 weeks’ recovery.
We found that the hGPCs tolerated cuprizone exposure at least
as well as their mouse counterparts and dispersed broadly
throughout the forebrain (Figures 2B and 2C). The hGPCs then
robustly generated new oligodendrocytes and effectivelyCell Reports 31, 107658, May 19, 2020 3
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Figure 2. hGPCs Differentiate as Myelinogenic Oligodendroglia in Response to Cuprizone Demyelination
(A) The schematic outlines the experimental design for neonatal engraftment followed by adult demyelination. Mice were transplanted with 2 3 105 hGPCs
perinatally, maintained on a control diet through 17 weeks of age, then placed on either a cuprizone-supplemented or normal diet for 12 weeks, then either
sacrificed or returned to standard diet, and killed at later time points.
(B andC) Serial coronal sections comparing dot-mapped distributions of human (hNA) cells in control (B) and cuprizone-fed (C) mice at 49 weeks of age, following
20 weeks of recovery on the control diet.
(D–G) Relative positions and abundance of human (red dots) andmouse (blue) TF-defined oligodendrocytes, mapped in 20-mmcoronal sections of corpus callosa
of mice engrafted with hGPCs neonatally, demyelinated as adults from 17-29 weeks of age, and then assessed either at the end of the cuprizone diet (D), 8 weeks
after return to control diet (E), or 20 weeks after cuprizone cessation (F). (G) Shows an untreated control, age-matched to (F).
(H) The density of human cells in the corpus callosum increases to a greater degree andmore rapidly in cuprizone-demyelinated brains than in untreated controls,
including during the 12-week period of cuprizone treatment (indicated in gray). **p < 0.001.
(I) By 8 weeks after the termination of cuprizone exposure, the density of human oligodendroglia was >5-fold greater in cuprizone-demyelinated than in untreated
control brains. ***p = 0.0006.
(J and K) By that 80-week recovery point, over half of all hGPCs engrafted in the corpus callosa of cuprizone-treated mice had differentiated as oligodendrocytes
(J), and accordingly, over half of all TF-defined callosal oligodendrocytes were human (K); in contrast, relatively few human oligodendrocytes were noted in
untreated chimeric brains. ***p < 0.0001.
(L) Substantial colonization by human glia evident in this remyelinated corpus callosum, after a 20-week recovery period (human nuclear antigen, magenta; myelin
basic protein, green).
(M) Chimeric whitematter populated, after cuprizone demyelination, by hGPC-derived oligodendroglia. hNA, red; TF, green; inset highlights relative abundance of
hNA+/TF+ human oligodendroglia. Scale bars: 100 mm (L) and 50 mm (M); inset scale bar: 25 mm.
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cuprizone (Figures 2D–2G and 2I–2M). Both the total number of
human cells and the percentage that differentiated as oligoden-
drocytes increased significantly faster and to a greater extent in
the cuprizone-fed mice than in their matched controls (Figures
2D–2G and 2H–2K). The density of human cells in the corpus cal-
losum of cuprizone-treated mice increased from 5,072 ± 1,611 at
4 months to 53,835 ± 5,898 cells/mm3 at one year; in contrast,4 Cell Reports 31, 107658, May 19, 2020over the same period, control mice exhibited a more modest
expansion of GPCs to 25,296 ± 4,959 cells/mm3 (p < 0.001 by
2-way ANOVA; F = 7.40) (Figure 2H). Importantly, the proportion
of all human cells that differentiated as TF-defined oligodendro-
cytes by 49 weeks was twice that in the cuprizone-treated
mice compared with their untreated controls (58.0% ± 4.8%
versus 26.6% ± 6.4%; p < 0.0001, F = 13.32; Figure 2J). Accord-
ingly, the terminal density of human oligodendrocytes in the
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Figure 3. hGPCs Differentiate and Remyelinate Axons after Transplant into Adult-Demyelinated Brain
(A) At 6 weeks of age, experimental mice were put on a diet containing 0.2% cuprizone, whereas littermate controls remained on a standard diet. At 10 weeks,
4 weeks into a 20-week cuprizone course, the mice were transplanted with 23 105 hGPCs. Mice were sacrificed for histology either at the end of the cuprizone
course (at 26 weeks) or after an additional 20-week recovery period (at 46 weeks).
(B and C) Maps show locations of individual human cells in 20-mm coronal hemi-sections of engrafted brains. (B) Transplantation of hGPCs into a normally
myelinated 10-week-old mouse yielded widespread engraftment, when mapped 36 weeks later at 46 weeks of age. (C) In cuprizone-treated mice, transplanted
hGPCs expanded to a significantly greater degree.
(D–H) Significantly more hGPCs differentiated as TF-defined oligodendrocytes in the cuprizone-demyelinated brains than in their untreated controls. (D) hGPCs
were more likely to differentiate as TF-expressing oligodendrocytes when transplanted into a demyelinating environment (left) than into a control brain (right).
(E and F) The absolute density of human cells (E) and relative proportion that differentiated as TF+ oligodendrocytes (F) in the corpus callosum were >5- and
(legend continued on next page)
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OPEN ACCESScuprizone-treated chimeric mice was 4.5-fold greater than that of
untreated chimeric mice (32,323 ± 5,850 versus 7,642 ± 3,095
hTF+ cells/mm3 at 49 weeks; p = 0.0006, F = 8.65; Figure 2I).
For these latter measurements, we immunostained for TF, which
is cytoplasmic and membrane localized, in tandem with human
nuclear antigen, so as to quantify and distinguish oligodendrocyte
numbers by the species of origin (Connor and Fine, 1987; Connor
et al., 1993).
These data indicate that cuprizone-induced demyelination
yielded a relative increase in both the absolute numbers and rela-
tive proportions of parenchymal hGPC-derived oligodendro-
cytes that, in turn, mediated the remyelination of denuded host
axons in these animals (Figures 2L and 2M). Thus, those hGPCs
already resident within the callosal white matter responded to
acute demyelination by expanding, with a fraction of their daugh-
ters differentiating as mature oligodendrocytes and remyelinat-
ing accessible axons. As such, these data indicate that hGPCs
can myelinate not only axons that have never been myelinated,
as in the adult shiverer, but also axons that have been previously
ensheathed by myelin.
hGPCs Can Remyelinate Axons when Delivered after
Initial Demyelination
We next asked if hGPCs delivered to the adult brain after initial
demyelination and during ongoing cuprizone exposure could
migrate and myelinate host axons and whether they were able
to myelinate denuded axons as effectively as hGPCs resident
in their host brains since neonatal development. To this end,
we next used prolonged cuprizone exposure to demyelinate
otherwise WT adult mice and transplanted hGPCs into these
demyelinating brains. In particular, to minimize the potential for
endogenous remyelination by remaining mouse GPCs, we
used a 20-week cuprizone course, which we found allowed
much less spontaneous remyelination than shorter periods of
cuprizone exposure (Figure 3A). We found that even when deliv-
ered into adult brain parenchyma 4 weeks after the onset of cu-
prizone treatment during active demyelination, the transplanted
hGPCs not only dispersed widely but also expanded more
robustly than in untreated controls (Figures 3B–3E). When the
cuprizone-fed mice were assessed at 16 weeks after hGPC
transplant (26 weeks of age), human oligodendrocytes were
apparent, having differentiated from the engrafted hGPCs. By
that point, more donor hGPCs had differentiated as oligodendro-
cytes in the cuprizone-demyelinated brains than in their un-
treated controls, suggesting both the preferential expansion of
hGPCs (Figure 3E) and the active induction of oligodendrocytic
phenotype by the demyelinated environment (Figure 3F). By
36 weeks post-transplant (46 weeks of age), after allowing 20
additional weeks for phenotypic differentiation, over a quarter
of all oligodendrocytes in the host white matter were of human>10-fold greater, respectively, in mice on the cuprizone diet than in their untrea
drocytes in the host white matter were of human origin. (H) The overall density of T
preserved at all time points. (E–G) *p < 0.05; **p < 0.01; ***p < 0.001.
(I–K) By 46 weeks, adult-transplanted hGPCs are admixed with murine cells in th
oligodendrocytes in the cuprizone-demyelinated callosal were of human donor or
the resident human cells had differentiated as TF-defined oligodendrocytes (K) (
Scale bars: 100 mm (I), 10 mm (J), and 50 mm (K).
6 Cell Reports 31, 107658, May 19, 2020origin (Figure 3G). Remarkably, the overall number and density
of TF-defined oligodendrocytes, whether of mouse or human
origin, were relatively preserved at all time points (Figure 3H).
The transplanted human cells proceeded to robustly differentiate
as oligodendrocytes and myelinate the demyelinated tissue,
such that by 46 weeks of age—36 weeks post-transplant—
much if not most of the forebrain white matter in these previously
cuprizone-demyelinated brains was of human origin (Figures 3I–
3K). Thus, hGPCs were able to effectively remyelinate mature
axons that had been previouslymyelinated in the brain and could
do so even when delivered to the adult brain after the onset of
demyelination.
Progenitor-Mediated Myelination Was Associated with
Functional Improvement
To assess the functional correlates of hGPC-mediated remyeli-
nation, we focused on adult-transplanted shiverer mice as the
more extreme and functionally impaired of the models we as-
sessed. To this end, a cohort of shiverer 3 rag2/ mice were
transplanted between 4–6 weeks of age with a total of 4 3 105
hGPCs, delivered as divided doses to the corpus callosum and
striatum bilaterally; a matched cohort of shiverers was sham in-
jected. The mice were then serially assessed at 18–20 weeks for
the following (Figure 4A): (1) motor function, asmeasured by Dig-
iGait automated treadmill analysis; (2) transcallosal conduction
amplitudes and velocities, relative to the sham-operated shiverer
controls, as determined by their stimulation-induced compound
action potentials in slice preparations; and (3) confocal and elec-
tron microscopic analyses of donor-derived myelin.
The DigiGait analysis (Figures 4B and 4C) revealed that by
18 weeks, the motor function and ambulation of transplanted
shiverer mice had improved overtly relative to untransplanted
controls: among a sample of 8 treated and 8 control mice, only
2 of the 8 untreated controls were able to remain on the moving
treadmill for the minimal 5-s testing period, whereas 7 of the 8
transplanted shiverers were able to do so on their first try, and
all 8 thereafter, with sustained treadmill-elicited ambulation at
10 m/s (p = 0.012; chi-square = 6.35, 1 degree of freedom [df];
Z = 2.52) (Figure 4C; Video S1).
These transplant-associated improvements in shiverer motor
performance were associated with normalization, relative to
WT mice, in the amplitude of the N1 (large myelinated fiber)
component of the transcallosal compound action potential (Fig-
ures 4D–4F), as assessed in slice preparations of geographically
homologous coronal sections of transplanted and untrans-
planted 18- to 19-week-old shiverers (n = 4 or 5 mice/group).
Indeed, sham-injected shiverer mice did not have a detectable
N1, whereas their transplanted counterparts did so reliably (Fig-
ure 4E). In addition, slices derived from the transplanted brains
exhibited a significant increase in the mean velocity of callosalted controls. (G) By 36 weeks post-transplant, over a quarter of all oligoden-
F-defined oligodendrocytes, whether of mouse or human origin, was relatively
e largely remyelinated corpus callosum (I). (J) By this point, most myelinating
igin (human nuclear antigen, red; MBP, green; DAPI, blue), and just as many of
human nuclear antigen, red; TF, green).
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(legend on next page)
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whereas the untreated shiverers had an N2 velocity of 305.2 ±
6.4 m/s, and slices derived from transplanted shiverers (with
analysis restricted to those with a measurable N1 component)
manifested a slower velocity to N2 of 285.5 ± 10.7 m/s
(p = 0.02 by one-way ANOVA; F = 4.07, 73 df), which was
indistinguishable from that of WT myelin WT controls (283.9 ±
4.0 m/s) (Figure 4G).
These measures of functional improvement in the engrafted
shiverers reflected the improved myelination of these
transplanted animals. Confocal imaging confirmed the oligoden-
drocytic differentiation of, and axonal myelination by, the trans-
planted human donor cells (Figures 4H–4J). In addition, ultra-
structural analysis confirmed that the hGPC-engrafted
shiverers developed compact myelin by the time of sacrifice,
12–14 weeks after transplantation, with the formation of major
dense lines (Figures 4M–4P), associated with and degrees of
myelin ensheathment not observed in untransplanted shiverer
controls (Figures 4K and 4L; compare to Figures 4M–4P).
hGPCs Activated Stereotypic Transcriptional Programs
after Cuprizone Demyelination
We next asked whether demyelination and its attendant activa-
tion of hGPCs was associated with transcriptional events that
might identify early determinants of progenitor cell mobilization,
aswell as those of astrocytic or oligodendrocytic fate. To thereby
identify the responses of hGPCs to demyelination in vivo, we iso-
lated them from cuprizone-demyelinated chimeric brains in
which they had been resident since birth, by using CD140a-
directed fluorescence-activated cell sorting (FACS), followed
by RNA-seq. To this end, neonatal rag1/ mice were trans-
planted with fetal hGPCs and maintained through 12 weeks of
age on a normal diet. At that point, control mice were continued
on a normal diet, whereas the experimental mice were transi-
tioned to a diet of 0.2% (w/w) cuprizone for 12 weeks to induce
oligodendrocytic death. The cuprizone-demyelinated mice were
then allowed to recover for an additional 12 weeks on a normalFigure 4. Myelination by Adult-Transplanted hGPCs Restores Function
(A) Mice were injected bilaterally in the corpus callosum and striatum at 4 weeks o
sequentially in a series of tests spanning behavior to anatomy. The arrows indica
(B) Sham-injected (top) and hGPC-transplanted (bottom) shiverers were videoed
(C) Of the 8 shiverer controls and 8 transplanted shiverers tested on the treadmill
engrafted mice did so on their first try (p = 0.012, chi-square; see Video S1), and
(D) Schematic of the measurements taken to assess the trans-callosal response
(E) Representative traces of normally myelinated shiverer heterozygous mice (W
strating restoration of the fast conduction N1 component in the transplanted mic
(F) N1 amplitude shows no significant difference between slice preparations der
plant-mediated normalization of the ratio of myelinated to unmyelinated axons in
zero and cannot be assessed as such.
(G) The slow N2 component conduction velocity of transplanted shiverer callos
different from that of WTs.
(H–P) All images were taken from 18-week-old shiverermice mice injected intrac
callosum (CC) of one hemisphere of an adult-engrafted shiverer. MBP, green. (I)
(hCyto) and MBP; the latter is necessarily human, as shiverer does not make MBP
respective color splits for human cytoplasm (red) andMBP (green), showing the m
(K–L) Electron micrographs of a sham-control CC demonstrating the thin mye
transplanted shiverers. (M–O) The variety of donor cell-ensheathed host axons, an
characteristic of compact myelin. (P) Higher power image of the detailed myelin
Scale bars: 100 mm (H), 20 mm (I–J), 500 nm (K and L), 200 nm (M–P), and 100 nm
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The callosal white matter was then dissected and dissociated,
and CD140a+ hGPCs were isolated by FACS. The RNA of these
hGPC isolates was then extracted and sequenced.
Principal-component analysis of these normalized RNA-seq
samples revealed tight clustering of control (CTR) samples,
which as a group were readily distinguished from their post-cu-
prizone counterparts (Figure 5A). Both the post-cuprizone and
CTR hGPCswere enriched for genes associated with early oligo-
dendroglial lineage, including CNP, GPR17, NKX2-2, OLIG1,
OLIG2, SOX10, CSPG4, and ST8SIA1, as well as the selection
marker PDGFRA/CD140a, with the latter validating the selec-
tivity and efficacy of the sort (Figure 5B). In contrast, the hGPC
isolates exhibited low to undetectable expression of a number
of neural stem cell, neural progenitor, endothelial, microglial,
neuronal, and astrocyticmarkers. Yet, although both groups pre-
sented with transcriptional signatures consistent with hGPC
phenotype, a total of 914 transcripts were differentially ex-
pressed between hGPCs following recovery from cuprizone
treatment and their control counterparts (adjusted p < 0.05). Of
these, 777 genes were upregulated in cuprizone-treated GPCs,
whereas 137were downregulated (Table S1). Functional analysis
of this gene set demonstrated that the cuprizone-treated hGPCs
differentially expressed gene ontologies reflecting cell prolifera-
tion, pathfinding and cell movement, and the initiation of myeli-
nation (Figure 6; Table S2).
Network Analysis Revealed That Cuprizone-Exposed
hGPCs Were Primed to Oligoneogenesis
To aid in interpreting these data (deposited to GEO:
GSE112557), a post-cuprizone hGPC expression network was
constructed based upon significantly enriched gene ontologies
and differentially expressed individual gene components
thereof. The network included 43 significantly enriched and rele-
vant functional terms, in addition to their contributing differen-
tially-expressed genes (network in Figure 5C; functionally segre-
gated heatmaps in Figure 5D; gene ontologies and componentsin shiverer Mice
f age with either cells or vehicle. When 18 weeks old, the mice were examined
te the sequence of tests, and italics indicate the relevant figures.
from below on a treadmill by using DigiGait.
, only 2 of 8 untreated mice were able to walk on the treadmill, whereas 7 of 8
all 8 did so on a second attempt.
to electrical stimulation of sampled slices.
T), sham-injected shiverers (sham), and transplanted shiverers (Tpts), demon-
e.
ived from normal WT and transplanted shiverer (Tpt) brains, suggesting trans-
the engrafted shiverer brain. Untreated shiverers have effective N1 velocities of
al slices was significantly more rapid than that of untreated shiverers and no
allosally at 4 weeks with hGPCs. (H) Low-magnification image of the corpus
Human oligodendrocytes, co-immunostained for human cytoplasmic antigen
. (J) A single mature donor-derived oligodendrocyte. Right-hand images show
any myelinating sheaths produced by a single hGPC-derived oligodendrocyte.
lin sheaths characteristic of shiverer. (M–P) Electron microscopy images of
d the insets show higher power images of the major dense lines (arrowheads),
ultrastrure of a donor cell-myelinated axon.
(M’–P’).
A B D
C
(legend on next page)
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OPEN ACCESSin Figure 6; complete ontology listings and network table in Table
S2). Community detection by modularity analysis was then car-
ried out to aggregate closely related functions and genes (Bas-
tian et al., 2009; Blondel et al., 2008). This analysis yielded four
distinct modules (M1–M4), which individually identified distinct
processes associated with the initiation of remyelination by cu-
prizone demyelination-mobilized hGPCs.
M1 revealed that the hGPCs recovering from cuprizone demy-
elination markedly upregulated their expression of myelinogene-
sis-associated genes, including MOG, MOBP, and CLDN11
(Goldman and Kuypers, 2015) (Figure 5C). Furthermore, several
genes previously noted to be induced during oligodendrocyte
differentiation and remyelination were also upregulated; these
genes included ST18 (Najm et al., 2013), PLEKHA1 (Chen
et al., 2015), and CMTM5 (Doyle et al., 2008), along with those
shown to be necessary for appropriate maturation of oligoden-
drocytes: CERS2 (Imgrund et al., 2009), LPAR1 (Garcı´a-Diaz
et al., 2015), GSN (Zuchero et al., 2015), KIF14 (Fujikura et al.,
2013), CNTN2 (Zoupi et al., 2018), ST3GAL3 (Yoo et al., 2015),
and WASF1/WAVE1 (Kim et al., 2006). Interestingly, M1 further
revealed that TCF7L2 signaling, a major driver of myelination
(Hammond et al., 2015; Zhao et al., 2016), is also strongly upre-
gulated in remyelinating hGPCs. Genes contributing to the
migration and pathfinding of GPCs were also upregulated
following cuprizone exposure; these genes included ROBO1
(Liu et al., 2012) and the class 3 semaphorin co-receptors
NRP2 (Boyd et al., 2013) and PLXNA3 (Xiang et al., 2012).
Within M2, a number of transcription factors and associated
signal effectors vital to oligodendrocyte movement and differenti-
ation were noted to be significantly enriched in the post-cuprizone
hGPCs. These included SMAD4 (Choe et al., 2014), transforming
growth factor b (TGF-b) (McKinnon et al., 1993), andNOTCH (Park
and Appel, 2003), as well as the pro-myelinogenic genes SMAD7
(Weng et al., 2012), PAK3 (Maglorius Renkilaraj et al., 2017), and
NOTCH3 (Zaucker et al., 2013). In contrast, the Notch pathway in-
hibitor of differentiation JAG1 was sharply repressed (John et al.,
2002), suggesting the incipient differentiation of these cells. Also
localizing to this module and upregulated in remyelinating GPCs
was GPR37, the expression of which attends and is necessary
for oligodendrocyte differentiation (Smith et al., 2017; Yang
et al., 2016). Interestingly, CIP2A, a transcriptional repressor of
GPR37, was profoundly downregulated in cuprizone-mobilized
hGPCs, again suggesting that cuprizone-demyelination triggers
the active disinhibition of oligodendrocytic differentiation by previ-
ously quiescent parenchymal hGPCs (Yang et al., 2016).
M3 consisted of several functional categories strongly
involved in myelination. These included transcripts involved inFigure 5. hGPC Transcriptional Networks Augur Compensatory Remy
Human glial chimeras weremaintained on either a cuprizone (CZN)-containing or c
were killed and their resident hGPCs isolated by CD140a-based FACS, which w
(A) Principal-component analysis revealed tight clustering of hGPCs separated f
(B) Isolated hGPCs were enriched for genes indicative of an oligodendrocytic fat
(C) A network was constructed from differentially expressed genes (circles) betwee
Ontology (GO) annotations (triangles) identified those pertinent and functionally
hGPCs. Gene node size was determined by the degree of connectivity, and anno
detection identified four modules (Ms) of closely related genes and annotations, fo
connectivity for each module. The complete list of differentially expressed genes
(D) A heatmap of genes identified in the previous GO network, organized by func
10 Cell Reports 31, 107658, May 19, 2020the transport and uptake of thyroid hormone and L-triiodothyro-
nine (Almazan et al., 1985; Bhat et al., 1979). M3 also included
genes associated with retinoid signaling, particularly RXRA and
the retinoid receptor complex partner RARG, the upregulation
of which was observed in hGPCs after cuprizone treatment
(Huang et al., 2011; Tomaru et al., 2009). This is of particular sig-
nificance, as this signaling family has previously been tied not
only to developmental myelination (de la Fuente et al., 2015)
but also to remyelination as well (Huang et al., 2011). M3 also
included genes associated with cholesterol and lipid uptake,
processes critical to myelination (Saher et al., 2005).
The fourth module included genes associated with the trans-
port and homeostatic regulation of iron and other multivalent
cations, which were upregulated following cuprizone demyelin-
ation. Iron, in particular, has been reported to be important in
the regulation of oligodendrocytic differentiation andmyelination
(Connor and Fine, 1987; Morath and Mayer-Pro¨schel, 2001). In
this regard, upregulation of MON1A and FXN, iron-meta-
bolism-associated genes strongly dysregulated in multiple
sclerosis lesions (Hametner et al., 2013), was observed in cupri-
zone-mobilized hGPCs. Similarly, we noted that genes encoding
calcium regulatory proteins associated with myelin maturation,
which includedCASR,GSN, and TRPC3 (Cheli et al., 2015; Kras-
now et al., 2018), were also increased in hGPCs after cuprizone
demyelination, as were transcripts involved in cyclic AMP
(cAMP) signaling, another modulator of oligodendrocyte differ-
entiation, in part by crosstalk with GPR37 and GPR17 (Simon
et al., 2016; Yang et al., 2016).
Overall, the pattern of differential gene expression by cupri-
zone-exposed hGPCs reflected in Figures 5 and 6 appears to
define an expression network typifying that of early-progenitor-
derived remyelination. As such, these data indicate that when
mobilized in response to antecedent cuprizone demyelination,
hGPCs activated a coherent set of transcriptional programs that
served to direct both oligodendrocytic differentiation andmyelino-
genesis. In addition, the many differentially expressed pathways
operative in these hGPCs, relative to those that had not under-
gone previous cuprizone exposure and demyelination-induced
mobilization, suggest that hGPCs resident within a chronically
demyelinating environment acquire transcriptional patterns that
may distinguish their functional competence and fate potential
from that of otherwise naive resident glial progenitor cells.
DISCUSSION
The congenitally hypomyelinated shiverermouse (MBPshi/shi) is a
naturally occurringmutant that lacksMBP and thus cannot makeelination after Demyelination
ontrol diet from 12–24weeks of age. Twelve weeks later, at 36 weeks, themice
ere then subjected to RNA-seq (n = 6).
rom post-CZN samples.
e; gene expression representative of other lineages was minimal.
n post-CZN andCTR hGPCs (adjusted p < 0.05); significantly associated Gene
related genes (gene nodes) that were differentially active in CZN-mobilized
tation node sizes scaled with their adjusted p values. Unsupervised modularity
r which a summary of annotations is provided with the percentage of total gene
is in Table S1, and complete network information is offered in Table S2.
tional category and module (M) membership.
(legend on next page)
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injection of hGPCs into neonatal shiverer mice results in the
widespread dispersal of the human donor cells, followed by their
oligodendrocytic differentiation and myelinogenesis (Windrem
et al., 2004, 2008). This ultimately leads to the complete or
near-complete myelination of the recipient’s brain, brainstem,
and spinal cord, attended by the clinical rescue of a large propor-
tion of the transplanted mice. Yet, notwithstanding the robust
developmental myelination of the host CNS by neonatally deliv-
ered hGPCs, in order for hGPC delivery to be a viable regenera-
tive strategy for treating adult demyelination—especially as
occurs in multicentric and diffuse myelin loss—the donor cells
must be capable of migrating within and myelinating adult brain
parenchyma.
In adults, oligodendrocytic loss contributes to diseases as
diverse as hypertensive and diabetic whitematter loss, traumatic
spinal cord and brain injury, multiple sclerosis and its variants,
and even the age-related white matter loss of the subcortical
dementias. All of these conditions are potential targets of glial
progenitor cell replacement therapy, recognizing that the adult
disease environment may limit this approach in a disease-spe-
cific fashion (Goldman, 2017; Goldman et al., 2012). For
instance, the chronically ischemic brain tissue of diabetics with
small vessel disease may require aggressive treatment of the
underlying vascular insufficiency before any cell replacement
strategy may be considered. Similarly, the inflammatory disease
environments of multiple sclerosis as well as of many of the leu-
kodystrophies present their own challenges, which need to be
overcome before cell-based remyelination can succeed
(Franklin and Ffrench-Constant, 2008, 2017; Goldman, 2016; Ip
et al., 2006); these include participation bymobilized GPCs in the
inflammatory response, potentially complicating therapeutic ef-
forts further (Falc~ao et al., 2018). Nonetheless, current disease-
modifying strategies for treating both vascular and autoimmune
diseases have advanced to the point where stabilization of the
disease environment can often be accomplished, such that
transplant-based remyelination for the structural repair of de-
myelinated adult white matter may now be feasible.
Despite concerns as to the ability of glial progenitor cells to re-
myelinate axons in disease environments, such as those associ-
ated with multiple sclerosis and the periventricular leukomalacia
of cerebral palsy, a number of studies have pointed to the cell-
intrinsic nature of oligodendrocytic differentiation block in these
cases (Fancy et al., 2009, 2014). These studies have suggested
that the inability of parenchymal glial progenitors to produce
myelinating oligodendrocytes in these conditions is a function
of stable epigenetic blocks in the differentiation potential of these
cells, imparted by the specific disease process or its anteced-
ents. Newly introduced naive hGPCs might, thus, be expected
to exercise unfettered differentiation and myelination compe-
tence in host brains and, as such, be able to remyelinate previ-Figure 6. Enrichment of Remyelination-Associated Pathways in Cupriz
(A) The significantly enriched functional categories highlighted in Figure 5C are org
exact test in Ingenuity Pathway Analysis.
(B) Genes differentially expressed by CZN-exposed hGPCs relative to controls, w
after cuprizone exposure are in red and those downregulated in blue. Activatio
expression implies activation (red) or inhibition (blue), following CZN exposure in p
12 Cell Reports 31, 107658, May 19, 2020ously demyelinated axons. Indeed, several prior studies have
indicated the ability of transplanted oligodendrocyte progenitors
to remyelinate adult-demyelinated central axons (Duncan et al.,
2009; Mozafari et al., 2015). To define the competence of hGPCs
to remyelinate axons when delivered to the demyelinated adult
brain, we used two different antigenic phenotypes of GPCs,
respectively defined as CD140a+ and A2B5+/PSA-NCAM,
each derived from fetal human brain tissue (Sim et al., 2011;
Windrem et al., 2008). These antigenic phenotypes are largely
but not completely homologous; the CD140a phenotype is the
major fraction of, and largely subsumed within, the A2B5+/
PSA-NCAM pool (Sim et al., 2011). We assessed the dispersal
and myelination competence of these cell types in two distinct
adult models of myelin deficiency, namely, the congenitally hy-
pomyelinated shiverermouse, as well as the normally myelinated
adult mouse, and the cuprizone-treated demyelinated adult
mouse.
In each of these model systems, the transplanted hGPCs
effectively restored myelin to the host brain. Donor-derived
myelination was robust when cells were delivered to the adult
shiverer brain, just as we had previously reported after hGPC
transplants in neonatal shiverer mice. The design of this experi-
ment was intended to mimic what might be encountered in the
post-natal treatment of a hypomyelinating leukodystrophy, and
the effective progenitor cell dispersal and myelination that we
observed augurs well for the potential use of this approach in
the treatment of children with congenital leukodystrophies. Simi-
larly, donor hGPC-derived oligodendrocyte differentiation and
axonal remyelination proved robust in response to cuprizone
demyelination, whether by hGPCs already resident within the
adult demyelinated brains or by those transplanted during and
after demyelination. This latter set of experiments, in particular,
provided an important proof-of-principle, showing that hGPCs
could remyelinate axons that had already been myelinated in
the past and that were then demyelinated in the setting of oligo-
dendrocyte loss; precisely such a scenario might be anticipated
in disorders such as progressive multiple sclerosis, in which the
remyelination of stably denuded residual axons might be ex-
pected to confer a functional benefit.
Indeed, in each of these experimental paradigms, we found
that the hGPCs, whether engrafted neonatally or transplanted
into adults, effectively dispersed throughout the forebrains,
even in normally myelinated mice, and differentiated as oligo-
dendroglia and myelinated demyelinated lesions as these
evolved or were encountered. These data suggest that trans-
planted fetal hGPCs are competent to disperse broadly and
differentiate as myelinogenic cells in the adult brain and, criti-
cally, that they are able to remyelinate previously myelinated
axons that have experienced myelin loss.
Having established the potential of hGPCs as myelinogenic
vectors, we then used RNA-seq of hGPCs extracted from theone-Exposed hGPCs
anized here by color-definedmodules. Enrichment was determined by Fisher’s
hich contributed to these differentially enriched pathways. Genes upregulated
n Z scores are also provided for those pathways for which collective gene
ost-CZN versus CTR hGPCs. Activation Z scores >1 were deemed significant.
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OPEN ACCESSbrains in which they had been resident during cuprizone expo-
sure to assess the transcriptional response of these cells to
demyelination and initial remyelination. By this means, we corre-
lated the demyelination-associated mobilization of resident
hGPCs to their subsequent transcriptional patterns, so as to
identify—in human cells isolated directly from the in vivo environ-
ment—those genes and pathways whose targeting might permit
the therapeutic modulation of both progenitor recruitment and
differentiated fate.
We found that mobilized hGPCs expressed a transcriptional
signature consistent with early remyelination, as has been noted
with demyelination-mobilized murine progenitors as well (Moyon
et al., 2015). Yet, human and mouse glial progenitors are quite
different phenotypes, and are distinct in their transcriptional sig-
natures (Lovatt et al., 2007; Sim et al., 2006, 2009; Zhang et al.,
2016), lineage restriction (Nunes et al., 2003), and daughter cell
morphologies (Oberheim et al., 2009). Accordingly, we noted a
number of activated pathways in demyelination-triggered
hGPCs not previously noted in models of murine demyelination.
These comprised a number of upstream directors of oligoden-
droglial fate choice and differentiation, which included TCF7L2,
TGF-b/SMAD4, and NOTCH-driven pathways. The activation
of each of these pathways was linked to the demyelination-asso-
ciated disinhibition of differentiation by these parenchymal
hGPCs, the oligodendrocytic maturation of which then enabled
the compensatory remyelination of denuded axons. In addition,
besides the activation of differentiation-associated pathways in
demyelination-stimulated hGPCs, our data also suggested the
critical importance during early remyelination of pathways
enabling iron transport and metabolism, as well as those facili-
tating cholesterol and lipid uptake, all of which are critically
important to oligodendrocytic myelinogenesis. Interestingly,
the identification of these pathways as differentially upregulated
during remyelination suggests that the efficiencies of both mye-
linogenesis and myelin maturation might be further potentiated
by metabolic optimization, and potentially even by dietary mod-
ulation. Together, these studies establish an operational ratio-
nale for assessing the ability of hGPCs to remyelinate demyeli-
nated lesions of the adult human brain, while providing a
promising set of molecular targets for the modulation of this pro-
cess in human cells.STAR+METHODS
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RUVSeq (version 1.6.2) N/A http://www.bioconductor.org/packages/release/
bioc/html/RUVSeq.html
EDASeq (version 2.6.2) N/A http://www.bioconductor.org/packages/release/
bioc/html/EDASeq.html
edgeR (version 3.14.0) N/A http://www.bioconductor.org/packages/release/
bioc/html/edgeR.html
DESeq2 (version 1.12.4) N/A http://www.bioconductor.org/packages/release/
bioc/html/DESeq2.html
Tximport (version 1.8.0) N/A https://bioconductor.org/packages/release/bioc/
html/tximport.html
Readr (version 1.3.1) N/A https://cran.rstudio.com/web/packages/readr/
index.html
Gephi (version 0.9.1) N/A https://gephi.org/
Ingenuity Pathway Analysis N/A https://digitalinsights.qiagen.com/
products-overview/discovery-insights-portfolio/
content-exploration-and-databases/qiagen-ipa/
pHeatmap (version 1.0.12) N/A https://github.com/raivokolde/pheatmap
ggplot2 (version 3.1.1) N/A https://ggplot2.tidyverse.org/
Cytoscape N/A https://cytoscape.org/
Other
Cryostat Hacker Instruments Model OTF
Cryostat Leica Biosyst. Cat#CM3050S
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Disposable microtome blades C.L. Sturkey 1000 Plus
Surgipath X-tra precleaned micro slides Leica Biosyst. Cat#121-6
FlowView300 Olympus N/A
DMi8 Leica Biosyst. N/A
DM6000B Leica Biosyst. N/A
DFC 360 FX camera Leica Biosyst. N/A
BX51 Olympus N/A
DP30BW camera Olympus N/A
Orca-R2 Digital CCD Camera Hamamatsu Cat#C10600-10B
MAC 5000 Ludl Electronic Cat#73005001
Focus DR Linear encoder Ludl Electronic Cat#99A420
STG 4’’x3’’ Stepper Ludl Electronic Cat#99S100-LE2-MBF
Olympus IX71 Inverted Research Microscope Olympus N/A
Agilent Bioanalyzer Agilent N/A
BD FACS AriaIIIU BD Bioscience N/A
HiSeq 2500 Illumina Inc. N/A
Nanodrop 1000 spectrophometer Nanodrop N/A
ClampFit Axon Instr. N/A
Multiclamp 700B amplifier Axon Instr. N/A
DigiData 1440 Axon Instr. N/A
PC10 two-step electrode puller Narishige N/A
DigiGait treadmill Mouse Specifics Inc N/A
Leica VT1000s Leica Biosyst. N/A
Critical Commercial Assays
Ovation PicoSL WTA System V2 NuGEN Cat#3312
Prelude Direct Lysis Modul NuGen Cat#1400-24
Deposited Data
Raw RNA-seq data GEO datasets GEO: GSE112557
R Analysis Script and Processed data This paper https://github.com/CTNGoldmanLab/
Cuprizone_2020
Article
ll
OPEN ACCESSRESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Steven A.
Goldman (steven_goldman@urmc.rochester.edu).
Materials availability
Any unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.
Data and Code Availability
Raw gene expression data are available via GEO, accession number GSE112557.
Exploration of our gene expression data can be carried out at https://genial.is/cuprizone. Full R analysis script and all processed
data are available at https://github.com/CTNGoldmanLab/Cuprizone_2020.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models and transplantation
Shiverer mice, engrafted as adults
HomozygousMBPshi/shi x rag2/, heterozygous controlMBPshi/- x rag2/, and myelin wild-type rag1/ immunodeficient mice were
bred and housed in a pathogen-free environment in accordance with University of Rochester animal welfare regulations. Mice fromCell Reports 31, 107658, May 19, 2020 e3
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OPEN ACCESSeach genotype were transplanted between the ages of 4-6 weeks with 1 3 105 hGPCs/1 ml/hemisphere (n = 2-4 mice/time-point/ge-
notype), delivered bilaterally to the genu of the corpus callosum at coordinates: AP0.8; ML ± 0.75; DV1.25, all relative to bregma.
Mice were injected with FK506 (5 mg/kg, i.p,.; Tecoland) daily for 3 days pre- and 3 days post-surgery. AllMBPshi/shi x Rag2/ mice
were killed at age 19-20 weeks, or when clinical morbidity, as defined in our animal welfare policy, was observed. For the myelin wild-
type mice, half of all rag2/ and rag1/ animals were sacrificed between 19-21 weeks of age, and the other half at 1 year.
Myelin wild-type mice, neonatally transplanted, cuprizone-demyelinated as adults
Homozygous rag1/ immunodeficient mice on a C57BL/6 background were bred in our colony. Animals were transplanted with
hGPCs neonatally, via bilateral injections delivered to the presumptive corpus callosum (Windrem et al., 2004), so as to engraft
newborn recipient brains before cuprizone demyelination. Beginning at 17 weeks of age, these mice were fed ad libitum a
diet containing 0.2% (w/w) cuprizone (S5891, BioServe) for 12 weeks and then returned to normal diet. Littermate and non-
littermate controls were maintained on a normal diet. Mice were sacrificed before diet (17 weeks), during diet (25 weeks), imme-
diately after diet completion (29 weeks), and after either 8 weeks (37 weeks old) or 20 weeks (49 weeks old) of post-cuprizone
recovery.
Myelin wild-type mice, cuprizone-demyelinated as adults, then transplanted
Homozygous rag1/mice were subjected to cuprizone demyelination as noted, for a 20-week period beginning at 6 weeks of age.
They were transplanted with hGPCs at 10 weeks of age, 4 weeks into their period of cuprizone demyelination. At that point, the mice
were transplanted with a total of 200,000 PSA-NCAM-/A2B5+ cells, delivered sterotaxically as 1x105 hGPCs/1 ml HBSS into the
corpus callosum bilaterally at the following coordinates: from bregma, AP 0.8 mm, ML ± 0.75; from dura, DV 1.25 mm. Upon re-
covery, mice were returned to their cages. Mice were injected with FK506 (5 mg/kg, i.p.; Tecoland) daily for 3 days pre- and 3 days
post-surgery. Mice were sacrificed during diet (18 weeks), immediately after diet completion (26 weeks), and after 20 weeks
(46 weeks old) of post-cuprizone recovery.
Cells
Human glial progenitor cells (hGPCs) were sorted from 18-22week g.a. human fetuses, obtained from the surgical pathology suite, by
either A2B5- or CD140a-directed isolation. Acquisition, dissociation and immunomagnetic sorting of A2B5+/PSA-NCAM- cells were
as described (Windrem et al., 2004). GPCs were isolated from dissociated tissue using a dual immunomagnetic sorting strategy:
depleting mouse anti-PSA-NCAM+ (Millipore, DSHB) cells, using microbead tagged rat anti-mouse IgM (Miltenyi Biotech), then se-
lecting A2B5+ (clone 105; ATCC, Manassas, VA) cells from the PSA-NCAM- pool, as described (Windrem et al., 2004, 2008). After
sorting, cells were maintained for 1-14 days in DMEM-F12/N1 with 10 ng/ml bFGF and 20 ng/ml PDGF-AA. Alternatively for some
experiments, CD140a/PDGFaR-defined GPCs were isolated and sorted using MACS as described (Sim et al., 2011), yielding an
enriched population of CD140+ glial progenitor cells.
METHOD DETAILS
Quantitative histology
All mice were perfusedwith calcium- andmagnesium-free HBSS followed by 4%paraformaldehyde. Brains were cryopreservedwith
6%, then 30% sucrose and embedded coronally in OCT (TissueTek). Brains were then cut at 20 mm on a Leica cryostat. Sections
were immunolabled for one or more of the antigenic markers listed below. The optical fractionator method was used to quantify
each cell phenotype in the corpus callosum, as: oligodendrocytes (transferrin), astrocytes (GFAP), and progenitors (PDGFRa). Quan-
tification was performed by using a computerized stereology system consisting of a BX-51 microscope (Olympus) equipped with a
Ludl (Hawthorne, NY) XYZ motorized stage, Heidenhain (Plymouth, MN) z axis encoder, an Optronics (East Muskogee, OK) Quanti-
Fire black and white video camera, a Dell (Round Rock, TX) PC workstation, and Stereo Investigator software (MicroBrightField,
Wiliston, VT). Within each corpus callosum, beginning at a random starting point where it crosses themidline, 3 sections equidistantly
spaced 480 mmapart were selected for analysis. The corpus callosumwas outlined from themidline to 1mm lateral, and all cells were
counted. Upper and lower exclusion zones of 10% of section thickness were used.
Functional assessment
Surgery
To assess the functional benefits effects of hGPC transplantation in young adult shiverer mice, 16 young adult shiverer x rag2 null mice
(8 male, 8 female) underwent surgery after weaning, at 4 wks of age. Half received human fetal CD140a-sorted cells, and half received
vehicle control. All micewere injected bilaterally at 4 points in the corpus callosum (AP:0.8 or + 0.9,ML: +/ 0.75). The bilateral rostral
injections were extended 3.0 mm ventrally into the striatum, with stops for partial injection at 3.0, 2.25 and 1.5 mm, while the
caudal injections were placed 1.25 mm ventral to the pial surface.
Motor and gait analysis
All 16 mice were tested individually on a DigiGait treadmill (Mouse Specifics, Inc., Framingham, MA). Treadmill speed for young,
healthy mice is 16 cm/sec; for both transplanted and control 18-week old shiverers, the speed was set to 10 cm/sec. Videos
were captured for 5 s periods, and the resultant images analyzed using DigiGait’s incorporated gait analysis software.e4 Cell Reports 31, 107658, May 19, 2020
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At 18-20 weeks of age, after their gait assessments, the mice were killed and coronal brain slices (350 mm) were prepared. Briefly,
slices were cut using a Leica VT1000s (Leica Biosystems, Buffalo Grove, IL), into ice-cold buffer (in mM: 127 NaCl, 26 NaHCO3, 1.2
KH2PO4, 1.9 KCl, 1.1 CaCl2, 2 MgSO4, 10 D-Glucose) bubbled with 95% O2 and 5% CO2. Slices were then transferred to a holding
chamber containing oxygenated artificial cerebrospinal fluid (ACSF; in mM: 127 NaCl, 26 NaHCO3, 1.2 KH2PO4, 1.9 KCl, 2.2 CaCl2, 1
MgSO4, 10 D-Glucose) for 30 min at 34
C, for another 30 min at room temperature, and then transferred to a submersion recording
chamber continually perfusedwith oxygenated ACSF at room temperature (rate: 2ml/min). Slices were equilibrated for at least 15min
before each recording.
Compound action potential recordings weremade using aMulticlamp 700B amplifier (Axon Instruments, Foster City, CA), sampled
at 10 kHz, digitized by a DigiData 1440A, and later analyzed offline by ClampFit (Axon software). Recording pipettes with resistances
ranging between 3-6MUwere pulled from standard borosilicate capillaries using a two-step electrode puller (PC-10, Narishige, Ami-
tyville, NY), and were filled with ACSF. A bipolar stimulating electrode and the recording electrode were placed on opposite sides of
the corpus callosum, equidistant to the midline of each slice. The distance between stimulating electrode and recording electrode
was between 1200-1600 mm. The first negative peak was measured as the myelinated component, and the second negative peak
was measured as the unmyelinated component of CAPs.
Immunostaining
Phenotyping of donor cells was accomplished by immunostaining for human nuclear antigen (Millipore, clone MAB1281), together
with one or more of the following, at the stated dilutions:Antigen Name dilution Catalog Company RRID
In vivo hGFAP Mouse anti-human glial fibrillary acidic prot 1:500 SMI-21R Covance AB_509979
hN Mouse anti-human nuclei, clone 235-1 1:800 MAB1281 Millipore AB_94090
hNG2 Mouse anti-NG2, clone 9.2.27 1:200 MAB2029 Millipore AB_94509
MBP Rat anti-myelin basic protein 1:25 ab7349 Abcam AB_305869
hPDGFRa Rabbit anti-human PDFaR, clone D13C6 1:300 5241S Cell Signal AB_10692773
Transferrin Rabbit anti-human transferrin 1:800 ab9538 Abcam AB_307325
CNP Rabbit anti-CNP 1:400 18527 Abcam AB_470266
Human
cytoplasm
Mouse anti-human cytoplasmic antigen,
STEM121
1:500 AB-121U050 Takara Bio AB_2632385
In vitro PSA-NCAM Mouse anti-PSA-NCAM, clone 2-2B 1:100 MAB5324 Millipore AB_95211
PSA-NCAM Mouse anti-PSA-NCAM supernatant, 5A5 1:1 5A5 DSHB AB_528392
A2B5 Mouse anti-A2B5 supernatant, clone 105 1:1 CRL-1520 ATCC CVCL_7946
CD140 Mouse anti-CD140a, Clone AR1 0.21 mg/106 cells 556001 BD Biosci. AB_396285
CD140a-PE PE-conj mouse anti-human CD140a, AR1 10 mL/ 106 cells 556002 BD Biosci AB_396286
Secondaries Rat anti-Mouse IgM MicroBeads 20 mL/107 cells 130-047-301 Miltenyi AB_244358
Rat anti-Mouse IgG2a+b MicroBeads 10 mL/107 cells 130-047-201 Miltenyi AB_244356
AlexaFluor 568 Goat anti-Mouse IgG (H+L) 1:400 A-11031 Invitrogen AB_144696
AlexaFluor 568 Goat anti-Mouse IgG1 1:400 A-21124 Invitrogen AB_2535766
AlexaFluor 488 Goat anti-Mouse IgG (H+L) 1:400 A-11029 Invitrogen AB_2534088
AlexaFluor 488 Goat anti-Mouse IgG1 1:400 A-21121 Invitrogen AB_2535764
AlexaFluor 647 Goat anti-Mouse IgG (H+L) 1:400 A-21235 Jackson AB_2535813
AlexaFluor 568 Goat anti-Rabbit IgG (H+L) 1:400 A-11036 Invitrogen AB_2534094
AlexaFluor 488 Goat anti-Rabbit IgG (H+L) 1:400 A-11034 Invitrogen AB_2576217
AlexaFluor 568 Goat anti-Rat IgG (H+L) 1:400 A-11077 Invitrogen AB_2534121
AlexaFluor 488 Goat anti-Rat IgG (H+L) 1:400 A-11006 Invitrogen AB_2534074QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
Statistics were performed using GraphPad Prism.Where variances were equal and data normally distributed, we used one-way anal-
ysis of variance (ANOVA); when unequal variances obtained, Kruskal-Wallis non-parametric analysis was used. All graphs are shown
as means ± SEM.Cell Reports 31, 107658, May 19, 2020 e5
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To observe transcriptional changes in hGPCs following demyelination, neonatal rag1/mice were transplanted with 23 105 hGPCs
as described above. At 12 weeks, mice either maintained a normal diet or were transitioned to a 0.2% (w/w) cuprizone diet fed ad
libitum until 24 weeks of age when they were returned to a normal diet. At 36 weeks, all mice were anesthetized with sodium pento-
barbital, perfused with ice cold HBSS+/+ (containing calcium and magnesium) (Thermo Fisher), and the brains extracted and placed
into fresh HBSS+/+ in a tissue culture plate. Excess HBSS+/+ was removed and the corpus callosum of each animal was isolated sur-
gically, minced, and suspended in HBSS/. Corpora callosa from twomice from the same experimental group were pooled for each
study. The tissue was transferred to a 15 mL conical tube and rinsed twice with HBSS/. The tube was filled to maximum volume
with HBSS/, and then centrifuged for 5 min at 1,500 rpm. The supernatant was then removed and 0.62 units Research Grade
Liberase DH (Roche) was added, and the samples then incubated at 37C for 40 min with gentle rocking. Following Liberase disso-
ciation, 2 mL 0.5% BSA in MEM (Thermo Fisher) supplemented with 500 units bovine pancreas DNase (Sigma) and 0.5 mL PD-FBS
(Cocalico Biologicals) was added to the sample. The sample was triturated with a p1000 Pipetman and then passed through a 70 mm
cell strainer. MEMcontaining 0.5%BSAwas then added to the tube to bring it to full volume, and the tube centrifuged at 1,500 rpm for
10 min. Dissociated cells were then tagged with anti-CD140a-PE and sorted via FACS as previously reported (Sim et al., 2011). Cells
were lysed and prepared for library construction via Prelude Direct Lysis Module (NuGEN) according to the manufacturer’s protocol.
Libraries were constructed usingOvation RNA-Seq SystemV2 (NuGEN) according tomanufacturer’s protocol and sequencedwith
a read length of paired-end 125bp on a HiSeq 2500 system (Illumina). Reads were demultiplexed and cleaned using Trimmomatic
(Bolger et al., 2014). Reads were aligned to human genomeGRCh38,p10 andmapped to Ensembl reference 91 via STAR 2.5.2b (Do-
bin et al., 2013), with quantMode set to TranscriptomeSAM. Gene abundances and expected counts were then calculated using
RSEM 1.3.0 (Li and Dewey, 2011). Expected counts were imported into R via tximport for differential expression analysis between
cuprizone and control hGPCs (R Core Team, 2017; Soneson et al., 2015). Low-expressing genes were removed prior to analysis
if their expected counts fell below a median of 3 in both conditions. Full within-lane normalization of samples was conducted using
EDASeq to adjust for GC-content effects prior to the generation of library size adjusted counts via DESeq2 (Love et al., 2014; Risso
et al., 2011). Differential expression between post-cuprizone and control hGPCs was then determined using DESeq2 following the
addition of a variance factor to the generalized linear model. This factor was calculated using RUVSeq’s RUVs function with all genes
set as in silico negative controls (Risso et al., 2014). Genes with an adjusted p value < 0.05 were considered significant. Only genes
with mean transcripts per million (TPM) > 5 in either group were kept for functional analysis, as they weremore likely to be biologically
significant.
For functional analysis and inference of gene interactivity, a gene ontology network was constructed. Differentially expressed
genes between both groups were analyzed in Ingenuity Pathway Analysis (QIAGEN) where 43 significantly enriched terms were
selected based on relevance, along with their contributing differentially expressed genes, to be used as nodes. Along with the un-
directed edges derived from gene-GO term associations, edges were further generated via IPA’s curated database connecting
genes with known interactions. Network visualization was carried out in Cytoscape (Shannon et al., 2003) with the determination
of modularity occurring in Gephi (Bastian et al., 2009). Nodes were clustered within their respective modules and aesthetically repo-
sitioned slightly.e6 Cell Reports 31, 107658, May 19, 2020
